ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 140 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 0.12 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,709,213 | -29.1% | 85,205 | -0.2% | 0.00% | -50.0% |
| Q2 2023 | $2,409,332 | -25.8% | 85,407 | -54.7% | 0.00% | 0.0% |
| Q1 2023 | $3,245,968 | +58.1% | 188,719 | +85.1% | 0.00% | 0.0% |
| Q4 2022 | $2,052,951 | -43.8% | 101,934 | -39.6% | 0.00% | -33.3% |
| Q3 2022 | $3,656,000 | -0.6% | 168,815 | +29.0% | 0.00% | 0.0% |
| Q2 2022 | $3,677,000 | +153.4% | 130,850 | +316.1% | 0.00% | +200.0% |
| Q1 2022 | $1,451,000 | -72.0% | 31,444 | -49.0% | 0.00% | -66.7% |
| Q4 2021 | $5,184,000 | +129.9% | 61,664 | +82.3% | 0.00% | +200.0% |
| Q3 2021 | $2,255,000 | -44.6% | 33,834 | -55.8% | 0.00% | -50.0% |
| Q2 2021 | $4,074,000 | +14.0% | 76,565 | -7.0% | 0.00% | 0.0% |
| Q1 2021 | $3,574,000 | +471.8% | 82,372 | +585.3% | 0.00% | – |
| Q4 2020 | $625,000 | +3372.2% | 12,020 | +2027.4% | 0.00% | – |
| Q3 2020 | $18,000 | -73.5% | 565 | -59.8% | 0.00% | – |
| Q2 2020 | $68,000 | – | 1,406 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Paradigm Biocapital Advisors LP | 300,434 | $25,254,000 | 7.21% |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,628,409 | $220,944,000 | 6.56% |
| Avidity Partners Management LP | 2,715,000 | $228,223,000 | 4.84% |
| Matrix Capital Management Company, LP | 4,349,279 | $365,600,000 | 4.07% |
| Affinity Asset Advisors, LLC | 117,500 | $9,877,000 | 3.59% |
| Integral Health Asset Management, LLC | 120,000 | $10,087,000 | 2.79% |
| Ghost Tree Capital, LLC | 80,000 | $6,725,000 | 2.41% |
| Ikarian Capital, LLC | 191,140 | $16,067,000 | 2.39% |
| Tri Locum Partners LP | 23,632 | $1,987,000 | 0.78% |
| Eventide Asset Management | 529,000 | $44,468,000 | 0.57% |